Tetraphase deal done, La Jolla Pharmaceutical taps Larry Edwards as CEO; Longtime Eli Lilly exec Michael Overdorf heads to Annexon as CBO
→ As La Jolla Pharmaceutical closed on their acquisition of Tetraphase on Wednesday, the San Diego biotech also announced that they’re taking the president and CEO right along with them as Larry Edwards steps in. Edwards, who had a 15-year run at Merck and was a global marketing director for the pharma giant, spent the last year at the helm at Tetraphase and 5 years overall in other roles.
Last November, George Tidmarsh walked away as La Jolla’s top exec “to pursue other interests” after their drug LJPC-401 flamed out for beta thalassemia patients and the study (LJ401-BT01) was summarily scrapped.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
